Phase 1/2 Findings Highlight RGX-202's Safety, Impact on Key

RGX-202, a gene therapy for Duchenne muscular dystrophy, was well tolerated with no therapy-related serious adverse effects in 3 patients who received the level 1 dosage.

Related Keywords

Canada , Arkansas , United States , Aravindhan Veerapandiyan , Olivier Danos , Manufacturing Innovation Center , World Muscle Society , International Congress , Arkansas Children , North Star Ambulatory Assessment , Innovation Center , Rgx 202 , Duchenne Muscular Dystrophy , Level 1 Dosage , Serum Creatine Kinase , Microdystrophin , Affinity Duchenne , Regenxbio ,